オピオイド使用障害 (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "オピオイド使用障害" in Japanese language version.

refsWebsite

Global rank Japanese rank

4^th place

24^th place

2^nd place

6^th place

218^th place

712^th place

low place

low place

447^th place

1,043^rd place

6^th place

146^th place

low place

low place

195^th place

376^th place

79^th place

235^th place

6,166^th place

9,537^th place

7^th place

63^rd place

acog.org

“Opioid Use and Opioid Use Disorder in Pregnancy”. ACOG (August 2017). 16 July 2018閲覧。

archive.org

American Psychiatric Association (2013), Diagnostic and Statistical Manual of Mental Disorders (5th ed.), Arlington: American Psychiatric Publishing, pp. 540–546, ISBN 978-0890425558

cdc.gov

“Commonly Used Terms”. www.cdc.gov (29 August 2017). 16 July 2018閲覧。
“Data Brief 294. Drug Overdose Deaths in the United States, 1999–2016”. CDC. 18 May 2018閲覧。

doi.org

“Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies”. BMJ 357: j1550. (April 2017). doi:10.1136/bmj.j1550. PMC 5421454. PMID 28446428.
“Opioid Use Disorders”. Child and Adolescent Psychiatric Clinics of North America 25 (3): 473–87. (July 2016). doi:10.1016/j.chc.2016.03.002. PMC 4920977. PMID 27338968.
“Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria”. Addiction 111 (7): 1177–87. (July 2016). doi:10.1111/add.13326. PMC 5071734. PMID 27028542.
GBD 2015 Mortality Causes of Death Collaborators (October 2016). “Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015”. Lancet 388 (10053): 1459–1544. doi:10.1016/S0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
“Neurobiologic Advances from the Brain Disease Model of Addiction”. The New England Journal of Medicine 374 (4): 363–71. (January 2016). doi:10.1056/NEJMra1511480. PMC 6135257. PMID 26816013.
Santoro, T. N.; Santoro, J. D. (2018). “Racial Bias in the US Opioid Epidemic: A Review of the History of Systemic Bias and Implications for Care”. Cureus 10 (12): e3733. doi:10.7759/cureus.3733. PMC 6384031. PMID 30800543.
Webster, LR (November 2017). “Risk Factors for Opioid-Use Disorder and Overdose.”. Anesthesia and Analgesia 125 (5): 1741–1748. doi:10.1213/ANE.0000000000002496. PMID 29049118.
“Risk Factors and Pooled Rate of Prolonged Opioid Use Following Trauma or Surgery: A Systematic Review and Meta-(Regression) Analysis”. The Journal of Bone and Joint Surgery. American Volume 100 (15): 1332–1340. (August 2018). doi:10.2106/JBJS.17.01239. PMID 30063596.
GBD 2013 Mortality Causes of Death Collaborators (January 2015). “Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013”. Lancet 385 (9963): 117–71. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.

drugabuse.gov

“Prescription opioid use is a risk factor for heroin use”. National Institute on Drug Abuse. 16 July 2018閲覧。

fda.gov

"FDA approves first buprenorphine implant for treatment of opioid dependence". U.S. Food and Drug Administration (FDA) (Press release). 26 May 2016. 2017年3月16日閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

“Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies”. BMJ 357: j1550. (April 2017). doi:10.1136/bmj.j1550. PMC 5421454. PMID 28446428.
“Opioid Use Disorders”. Child and Adolescent Psychiatric Clinics of North America 25 (3): 473–87. (July 2016). doi:10.1016/j.chc.2016.03.002. PMC 4920977. PMID 27338968.
“Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria”. Addiction 111 (7): 1177–87. (July 2016). doi:10.1111/add.13326. PMC 5071734. PMID 27028542.
GBD 2015 Mortality Causes of Death Collaborators (October 2016). “Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015”. Lancet 388 (10053): 1459–1544. doi:10.1016/S0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
“Neurobiologic Advances from the Brain Disease Model of Addiction”. The New England Journal of Medicine 374 (4): 363–71. (January 2016). doi:10.1056/NEJMra1511480. PMC 6135257. PMID 26816013.
Santoro, T. N.; Santoro, J. D. (2018). “Racial Bias in the US Opioid Epidemic: A Review of the History of Systemic Bias and Implications for Care”. Cureus 10 (12): e3733. doi:10.7759/cureus.3733. PMC 6384031. PMID 30800543.
Webster, LR (November 2017). “Risk Factors for Opioid-Use Disorder and Overdose.”. Anesthesia and Analgesia 125 (5): 1741–1748. doi:10.1213/ANE.0000000000002496. PMID 29049118.
“Risk Factors and Pooled Rate of Prolonged Opioid Use Following Trauma or Surgery: A Systematic Review and Meta-(Regression) Analysis”. The Journal of Bone and Joint Surgery. American Volume 100 (15): 1332–1340. (August 2018). doi:10.2106/JBJS.17.01239. PMID 30063596.
GBD 2013 Mortality Causes of Death Collaborators (January 2015). “Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013”. Lancet 385 (9963): 117–71. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.

ncbi.nlm.nih.gov

“3 Patient Assessment”. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction.. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). (2004)
“Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies”. BMJ 357: j1550. (April 2017). doi:10.1136/bmj.j1550. PMC 5421454. PMID 28446428.
“Opioid Use Disorders”. Child and Adolescent Psychiatric Clinics of North America 25 (3): 473–87. (July 2016). doi:10.1016/j.chc.2016.03.002. PMC 4920977. PMID 27338968.
“Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria”. Addiction 111 (7): 1177–87. (July 2016). doi:10.1111/add.13326. PMC 5071734. PMID 27028542.
GBD 2015 Mortality Causes of Death Collaborators (October 2016). “Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015”. Lancet 388 (10053): 1459–1544. doi:10.1016/S0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
“Neurobiologic Advances from the Brain Disease Model of Addiction”. The New England Journal of Medicine 374 (4): 363–71. (January 2016). doi:10.1056/NEJMra1511480. PMC 6135257. PMID 26816013.
Santoro, T. N.; Santoro, J. D. (2018). “Racial Bias in the US Opioid Epidemic: A Review of the History of Systemic Bias and Implications for Care”. Cureus 10 (12): e3733. doi:10.7759/cureus.3733. PMC 6384031. PMID 30800543.
GBD 2013 Mortality Causes of Death Collaborators (January 2015). “Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013”. Lancet 385 (9963): 117–71. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.

pmc.ncbi.nlm.nih.gov

nytimes.com

Hughes, Evan (2 May 2018). “The Pain Hustlers”. New York Times 3 May 2018閲覧。

samhsa.gov

Substance Use and Mental Health Services Administration (2014年9月30日). “Substance Use Disorders”. 3 May 2018閲覧。
“Treatment for Substance Use Disorders”. Substance Abuse and Mental Health Services Administration (October 2014). 16 July 2018閲覧。

who.int

“WHO | Information sheet on opioid overdose”. WHO. 2019年4月6日閲覧。

wsj.com

jp.wsj.com

Steele, Anne. “オピオイド依存の診断、過去7年で500％増加＝米調査”. WSJ Japan. 2023年5月15日閲覧。